4.8 Article

Contribution of reactive oxygen species to cerebral amyloid angiopathy, vasomotor dysfunction, and microhemorrhage in aged Tg2576 mice

Publisher

NATL ACAD SCIENCES
DOI: 10.1073/pnas.1414930112

Keywords

Alzheimer's disease; cerebral amyloid angiopathy; reactive oxygen species; NADPH oxidase; vasomotor dysfunction

Funding

  1. NIH-National Institute of Neurological Disorders and Stroke [1R01 NS071011-01A1, AG13956]
  2. Harrington/Zhu Alzheimer Research Fund from the Barnes-Jewish Hospital Foundation
  3. McDonnell Center for Systems Neuroscience grant

Ask authors/readers for more resources

Cerebral amyloid angiopathy (CAA) is characterized by deposition of amyloid beta peptide (A beta) within walls of cerebral arteries and is an important cause of intracerebral hemorrhage, ischemic stroke, and cognitive dysfunction in elderly patients with and without Alzheimer's Disease (AD). NADPH oxidase-derived oxidative stress plays a key role in soluble A beta-induced vessel dysfunction, but the mechanisms by which insoluble A beta in the form of CAA causes cerebrovascular (CV) dysfunction are not clear. Here, we demonstrate evidence that reactive oxygen species (ROS) and, in particular, NADPH oxidase-derived ROS are a key mediator of CAA-induced CV deficits. First, the NADPH oxidase inhibitor, apocynin, and the nonspecific ROS scavenger, tempol, are shown to reduce oxidative stress and improve CV reactivity in aged Tg2576 mice. Second, the observed improvement in CV function is attributed both to a reduction in CAA formation and a decrease in CAA-induced vasomotor impairment. Third, anti-ROS therapy attenuates CAA-related microhemorrhage. A potential mechanism by which ROS contribute to CAA pathogenesis is also identified because apocynin substantially reduces expression levels of ApoE-a factor known to promote CAA formation. In total, these data indicate that ROS are a key contributor to CAA formation, CAA-induced vessel dysfunction, and CAA-related microhemorrhage. Thus, ROS and, in particular, NADPH oxidase-derived ROS are a promising therapeutic target for patients with CAA and AD.

Authors

I am an author on this paper
Click your name to claim this paper and add it to your profile.

Reviews

Primary Rating

4.8
Not enough ratings

Secondary Ratings

Novelty
-
Significance
-
Scientific rigor
-
Rate this paper

Recommended

No Data Available
No Data Available